Antibody Contract Development And Manufacturing Organization Market Size (2024 - 2029)

Antibody Contract Development And Manufacturing Organization Market Analysis

The Antibody Contract Development And Manufacturing Organization Market size is estimated at USD 23.63 billion in 2024, and is expected to reach USD 51.87 billion by 2029, growing at a CAGR of 14% during the forecast period (2024-2029).

The market is driven by the increasing rate of clinical research and increasing funding for the development of antibody therapeutics, the rising incidence of cancer, the high cost of manufacturing antibodies, and challenges associated with the manufacturing of antibodies.

For instance, in October 2022, BARDA, an agency within the US Health and Human Services (HHS), specifically within the HHS Administration for Strategic Preparedness and Response (ASPR), awarded Vir approximately USD 50 million in new funding to advance the development of novel monoclonal antibody (mAb) candidates and delivery solutions to widen the applicability of mAbs in COVID-19. Similarly, in March 2023, Antiverse Ltd (Antiverse) raised USD 3 million in funding, enabling in-house antibody development. Thus, high investment in developing and researching antibody drugs is expected to fuel the demand for CDMO services during the forecast period.

Further, antibody is a potential treatment option for cancer, and the growing burden of cancer is expected to increase drug development and manufacturing activities, which are likely to propel demand for CDMO services during the forecast period. For instance, as per the Canadian Cancer Statistics 2023 report, about 239.2 thousand new cancer cases were reported in 2023 in Canada, compared to 233.9 thousand in 2022. Thus, the growing burden of cancer is expected to create the demand for drug research and manufacturing services, which is expected to contribute to the segment’s growth. According to the data updated by the National Cancer Center of Japan in 2022, an estimated 96.4 thousand new prostate cancer cases, 40.4 thousand new liver cancer cases, and 37.1 thousand malignant lymphoma cases were diagnosed in Japan in 2022. Thus, market expansion is expected to be propelled by the projected rise in cancer prevalence.

Strategic activities by market players, such as collaborations, partnerships, and mergers and acquisitions, are expected to propel the market's growth during the forecast period. For instance, in April 2022, Asahi Kasei Medical expanded its business vertical into the antibody CDMO space by acquiring Bionova Scientific LLC, a biologics CDMO service provider. Additionally, in September 2023, Samsung Biologics, a Korean CDMO, announced an agreement for the large-scale manufacturing of an antibody cancer drug substance with global biopharma company Bristol Myers Squibb.

All these factors mentioned above, such as growing funding for antibody development, increasing cancer burden, and strategic activities by the market players, are expected to boost the market’s growth during the forecast period. However, quality concerns during outsourcing and minimal outsourcing practices among large biopharma companies may hinder market expansion during the forecast period.

Antibody Contract Development And Manufacturing Organization Industry Segmentation

As per the scope of the report, antibody contract development and manufacturing organizations (CDMOs) are specialized companies that provide services related to developing, producing, and manufacturing antibodies. These organizations offer expertise in antibody development, including cell line development, process optimization, analytical testing, and large-scale production. They play a crucial role in helping biopharmaceutical companies bring therapeutic antibodies to market by providing specialized facilities and equipment. The antibody contract development and manufacturing organization market is segmented by product, source, therapeutic area, end user, and geography. In terms of product, monoclonal antibodies, polyclonal antibodies, and other products segment the market. In terms of source, the market is segmented as mammalian and microbial. The market is segmented by therapeutic areas such as oncology, neurology, cardiology, infectious diseases, and immune-mediated disorders. By end user, the market is segmented as biopharmaceutical companies, research laboratories, and other end users. The market is segmented by geography, such as North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD) for the above segments.